Non Muscle Invasive Bladder Cancer clinical trials

Explore recruiting non muscle invasive bladder cancer clinical trials.

Recruiting non muscle invasive bladder cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Muscle Invasive Bladder Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery

Czechia

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer

Denmark, Norway, Sweden, Iceland

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 1b/2, dose expansion, open-label study to evaluate safety and anti-tumor activity of intravesical instillation of TARA-002 in adults with high-grade non-muscle invasive bladder cancer.

Spain, Romania

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A study of enfortumab vedotin given in the bladder for treatment of patients with non-muscle invasive bladder cancer (NMIBC).

France, Spain, Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A phase II prospective, open-label, multi-centre, single arm study of sasanlimab plus sacituzumab govitecan in BCG (Bacillus Calmette-Guérin)- unresponsive non-muscle invasive bladder cancer (NMIBC) patients.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Non Muscle Invasive Bladder Cancer trials by city

Non Muscle Invasive Bladder Cancer in Toronto Non Muscle Invasive Bladder Cancer in Vancouver Non Muscle Invasive Bladder Cancer in Montreal Non Muscle Invasive Bladder Cancer in Calgary Non Muscle Invasive Bladder Cancer in Edmonton Non Muscle Invasive Bladder Cancer in Ottawa Non Muscle Invasive Bladder Cancer in Winnipeg Non Muscle Invasive Bladder Cancer in Quebec City Non Muscle Invasive Bladder Cancer in Hamilton Non Muscle Invasive Bladder Cancer in Kitchener Non Muscle Invasive Bladder Cancer in London Non Muscle Invasive Bladder Cancer in Halifax Non Muscle Invasive Bladder Cancer in New York Non Muscle Invasive Bladder Cancer in Los Angeles Non Muscle Invasive Bladder Cancer in Chicago Non Muscle Invasive Bladder Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease